Cell Signaling Market is expected to reach USD 3.51 billion by 2022

Tuesday, June 6, 2017 Research News
Email Print This Page Comment bookmark
Font : A-A+

LONDON, June 6, 2017 /PRNewswire/ -- Highlights

·         The cell signaling market is expected to reach USD

3.51 billion by 2022 from USD 2.53 billion in 2017, at a CAGR of 6.8%. Factors such as increasing incidence of various chronic diseases; rising funding for cell-based research activities; introduction of innovative and
advanced instruments; and growing biotech and biopharmaceutical industries are driving the global cell signaling market.

·         The cell signaling market is categorized based on type, product, technology, pathway, application, and region.

·         The type segment includes endocrine, paracrine, autocrine, juxtacrine, and other types (neuronal and intracrine signaling).

·         The endocrine segment is estimated to account the largest share of the cell signaling market in 2017.

·         In 2017, the Akt segment is estimated to account the largest share of the cell signaling market.

The cell signaling market is expected to reach USD 3.51 billion by 2022 from USD 2.53 billion in 2017, at a CAGR of 6.8%. Factors such as increasing incidence of various chronic diseases; rising funding for cell-based research activities; introduction of innovative and advanced instruments; and growing biotech and biopharmaceutical industries are driving the global cell signaling market.The cell signaling market is categorized based on type, product, technology, pathway, application, and region. The type segment includes endocrine, paracrine, autocrine, juxtacrine, and other types (neuronal and intracrine signaling). The endocrine segment is estimated to account the largest share of the cell signaling market in 2017. By product, the cell signaling market is categorized into consumables (antibodies, reagents, assay kits and other consumables) and instruments. In 2017, the consumables segment is estimated to account the largest share of the market. The technology segment of the cell signaling market includes microscopy, western blotting, immunohistochemistry (IHC), flow cytometry, enzyme-linked immunosorbent assay (ELISA), mass spectrometry, and other technologies (immunofluorescence and immunoprecipitation). The microscopy segment is estimated to account for the largest share of the cell signaling market in 2017. On the basis of the pathway, the cell signaling market is categorized into Akt, AMP-activated protein kinase (AMPK), ErbB/HER, Hedgehog (Hh), Janus kinase and signal transducer and activator of transcription (JAK/STAT), NF-?B, Notch, and other signaling pathways. In 2017, the Akt segment is estimated to account the largest share of the cell signaling market. The application segment of cell signaling market includes research applications (cancer research, immunology research, stem cells research, and other research applications) and medical applications. The research applications segment is estimated to account for the largest share of the cell signaling market in 2017. Geographically, the cell signaling market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). The major players in the cell signaling market include Becton, Dickinson and Company (U.S.), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), QIAGEN N.V. (Netherlands), Beckman Coulter, Inc. (U.S.) (a subsidiary of Danaher Corporation), Promega Corporation (U.S.), PerkinElmer Inc. (U.S.), Bio-Techne Corporation (U.S.), and Abcam plc (U.K.) Research Coverage:Apart from comprehensive geographic analysis, product analysis, and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. The company profiles also comprise of product portfolios, developments, and strategies adopted by the market players to maintain and increase their shares in the market. This market research data can help key players and new entrants make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output to remain successful in the cell signaling market.Reasons to Buy the Report:This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned strategies to strengthening their shares in the cell signaling market.The report provides insights on the following pointers:• Market Penetration: Comprehensive information on product portfolios of the top players in the cell signaling market. The report analyzes the cell signaling market, by type, product, technology, pathway, application, and region. • Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the cell signaling market• Competitive Assessment: In-depth assessment of market strategies, geographic and business segments, and product portfolios of the leading players in the cell signaling market• Market Development: Comprehensive information about emerging markets. This report analyses the cell signaling market across geographies. • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cell signaling marketDownload the full report: https://www.reportbuyer.com/product/4908889/About ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishershttp://www.reportbuyer.comFor more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com Tel: +44 208 816 85 48 Website: www.reportbuyer.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cell-signaling-market-is-expected-to-reach-usd-351-billion-by-2022-300469573.html

SOURCE ReportBuyer



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook